WHO ICTRP trial
Study of XL184 in subjects with advanced solid tumors
EUCTR2009-012964-14-GB · EU Clinical Trials Register · Not Recruiting
Key facts
| Trial ID | EUCTR2009-012964-14-GB |
|---|---|
| Public title | Study of XL184 in subjects with advanced solid tumors |
| Scientific title | A randomized discontinuation study of XL184 in subjects with advanced solid tumors |
| Primary sponsor | Exelixis Inc |
| Registry | EU Clinical Trials Register |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): yes Therapeutic confirmatory - (Phase III): no Therapeutic use (Phase IV): no |
| Countries | United States;Taiwan;Belgium;Israel;United Kingdom |
| Conditions | To evaluate the efficacy of XL184 in subjects with one of the following advanced solid tumors: a. Breast Cancer b. Gastric and Gastroesophageal Junction Cancer c. Hepatocellular Carcinoma (HCC) d. Melanoma e. Non-small Cell Lung Cancer f… |
| Interventions | Product Name: XL184 Product Code: XL184 Pharmaceutical Form: Capsule, hard INN or Proposed INN: Cabozantinib CAS Number: 1140909-48-3 Current Sponsor code: XL184 Concentration unit: mg milligram(s) Concentration type: equal Concentration… |
| Registration date | Mar 24, 2011 |
| Target size | 250 |
| Secondary IDs | XL184-203;NCT00940225;2009-012964-14-BE |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: